A reappraisal of the clinical efficacy of nebulized flunisolide in pediatric asthma: The Italian experience

Ahmad Kantar, Salman Mroueh, Alessandro Fiocchi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Flunisolide (FLU) is a synthetic corticosteroid with potent topical anti-inflammatory activity. Its oral bioavailability is poor (6.7%). After gastrointestinal and lung absorption, the drug undergoes rapid and extensive first-pass metabolism by the liver to an inactive 6β-hydroxylated metabolite. Plasma half-life is estimated to be 3.9 to 4.6 hours. FLU has a low volume of distribution at steady state and a short terminal half-life after inhalation (96 L and 1.6 hour, respectively). FLU, like budesonide, has a short pulmonary residence time and it is hypothesized that it may undergo esterification in the cell due to the presence of a free hydroxyl group at C21. Nebulization may offer important advantages over other inhalation methods. Nebulizers allow drug delivery in very young children through passive inhalation, depending less on patient coordination and cooperation. Comparative studies indicate that FLU is nebulized to a better advantage than beclomethasone dipropionate and budesonide. This is attributed to its elevated water solubility. The aim of this article is to outline the factors that influence drug nebulization and the pharmacokinetics-pharmacodynamics of FLU compared to other inhaled corticosteroids. In addition, we report a series of clinical data regarding the efficacy of nebulized FLU with focus on the Italian experience. Overall, the physicochemical characteristics and pharmacokinetic profile of FLU favor its use for nebulization. Clinical data indicate that nebulized FLU is effective in asthma treatment in infants and children. Side effects were not reported at the commonly used doses.

Original languageEnglish
Pages (from-to)671-687
Number of pages17
JournalAllergy and Asthma Proceedings
Volume28
Issue number6
DOIs
Publication statusPublished - Nov 2007

Fingerprint

flunisolide
Asthma
Pediatrics
Inhalation
Budesonide
Half-Life
Adrenal Cortex Hormones
Pharmacokinetics
Pharmaceutical Preparations
Beclomethasone
Lung
Esterification
Nebulizers and Vaporizers
Patient Compliance

Keywords

  • Asthma
  • Clinical
  • Flunisolide
  • Nebulization
  • Pediatric
  • Pharmacodynamics
  • Pharmacokinetics

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

A reappraisal of the clinical efficacy of nebulized flunisolide in pediatric asthma : The Italian experience. / Kantar, Ahmad; Mroueh, Salman; Fiocchi, Alessandro.

In: Allergy and Asthma Proceedings, Vol. 28, No. 6, 11.2007, p. 671-687.

Research output: Contribution to journalArticle

@article{22e16e43b76343ce90f7a82504a5da35,
title = "A reappraisal of the clinical efficacy of nebulized flunisolide in pediatric asthma: The Italian experience",
abstract = "Flunisolide (FLU) is a synthetic corticosteroid with potent topical anti-inflammatory activity. Its oral bioavailability is poor (6.7{\%}). After gastrointestinal and lung absorption, the drug undergoes rapid and extensive first-pass metabolism by the liver to an inactive 6β-hydroxylated metabolite. Plasma half-life is estimated to be 3.9 to 4.6 hours. FLU has a low volume of distribution at steady state and a short terminal half-life after inhalation (96 L and 1.6 hour, respectively). FLU, like budesonide, has a short pulmonary residence time and it is hypothesized that it may undergo esterification in the cell due to the presence of a free hydroxyl group at C21. Nebulization may offer important advantages over other inhalation methods. Nebulizers allow drug delivery in very young children through passive inhalation, depending less on patient coordination and cooperation. Comparative studies indicate that FLU is nebulized to a better advantage than beclomethasone dipropionate and budesonide. This is attributed to its elevated water solubility. The aim of this article is to outline the factors that influence drug nebulization and the pharmacokinetics-pharmacodynamics of FLU compared to other inhaled corticosteroids. In addition, we report a series of clinical data regarding the efficacy of nebulized FLU with focus on the Italian experience. Overall, the physicochemical characteristics and pharmacokinetic profile of FLU favor its use for nebulization. Clinical data indicate that nebulized FLU is effective in asthma treatment in infants and children. Side effects were not reported at the commonly used doses.",
keywords = "Asthma, Clinical, Flunisolide, Nebulization, Pediatric, Pharmacodynamics, Pharmacokinetics",
author = "Ahmad Kantar and Salman Mroueh and Alessandro Fiocchi",
year = "2007",
month = "11",
doi = "10.2500/aap.2007.28.2979",
language = "English",
volume = "28",
pages = "671--687",
journal = "Allergy and Asthma Proceedings",
issn = "1088-5412",
publisher = "OceanSide Publications Inc.",
number = "6",

}

TY - JOUR

T1 - A reappraisal of the clinical efficacy of nebulized flunisolide in pediatric asthma

T2 - The Italian experience

AU - Kantar, Ahmad

AU - Mroueh, Salman

AU - Fiocchi, Alessandro

PY - 2007/11

Y1 - 2007/11

N2 - Flunisolide (FLU) is a synthetic corticosteroid with potent topical anti-inflammatory activity. Its oral bioavailability is poor (6.7%). After gastrointestinal and lung absorption, the drug undergoes rapid and extensive first-pass metabolism by the liver to an inactive 6β-hydroxylated metabolite. Plasma half-life is estimated to be 3.9 to 4.6 hours. FLU has a low volume of distribution at steady state and a short terminal half-life after inhalation (96 L and 1.6 hour, respectively). FLU, like budesonide, has a short pulmonary residence time and it is hypothesized that it may undergo esterification in the cell due to the presence of a free hydroxyl group at C21. Nebulization may offer important advantages over other inhalation methods. Nebulizers allow drug delivery in very young children through passive inhalation, depending less on patient coordination and cooperation. Comparative studies indicate that FLU is nebulized to a better advantage than beclomethasone dipropionate and budesonide. This is attributed to its elevated water solubility. The aim of this article is to outline the factors that influence drug nebulization and the pharmacokinetics-pharmacodynamics of FLU compared to other inhaled corticosteroids. In addition, we report a series of clinical data regarding the efficacy of nebulized FLU with focus on the Italian experience. Overall, the physicochemical characteristics and pharmacokinetic profile of FLU favor its use for nebulization. Clinical data indicate that nebulized FLU is effective in asthma treatment in infants and children. Side effects were not reported at the commonly used doses.

AB - Flunisolide (FLU) is a synthetic corticosteroid with potent topical anti-inflammatory activity. Its oral bioavailability is poor (6.7%). After gastrointestinal and lung absorption, the drug undergoes rapid and extensive first-pass metabolism by the liver to an inactive 6β-hydroxylated metabolite. Plasma half-life is estimated to be 3.9 to 4.6 hours. FLU has a low volume of distribution at steady state and a short terminal half-life after inhalation (96 L and 1.6 hour, respectively). FLU, like budesonide, has a short pulmonary residence time and it is hypothesized that it may undergo esterification in the cell due to the presence of a free hydroxyl group at C21. Nebulization may offer important advantages over other inhalation methods. Nebulizers allow drug delivery in very young children through passive inhalation, depending less on patient coordination and cooperation. Comparative studies indicate that FLU is nebulized to a better advantage than beclomethasone dipropionate and budesonide. This is attributed to its elevated water solubility. The aim of this article is to outline the factors that influence drug nebulization and the pharmacokinetics-pharmacodynamics of FLU compared to other inhaled corticosteroids. In addition, we report a series of clinical data regarding the efficacy of nebulized FLU with focus on the Italian experience. Overall, the physicochemical characteristics and pharmacokinetic profile of FLU favor its use for nebulization. Clinical data indicate that nebulized FLU is effective in asthma treatment in infants and children. Side effects were not reported at the commonly used doses.

KW - Asthma

KW - Clinical

KW - Flunisolide

KW - Nebulization

KW - Pediatric

KW - Pharmacodynamics

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=38349095658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38349095658&partnerID=8YFLogxK

U2 - 10.2500/aap.2007.28.2979

DO - 10.2500/aap.2007.28.2979

M3 - Article

C2 - 17883883

AN - SCOPUS:38349095658

VL - 28

SP - 671

EP - 687

JO - Allergy and Asthma Proceedings

JF - Allergy and Asthma Proceedings

SN - 1088-5412

IS - 6

ER -